FDA Inspection 1173461 — Cadila Pharmaceuticals Limited
The FDA completed an inspection of Cadila Pharmaceuticals Limited on Jun 17, 2022 in Ahmedabad. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 17, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Ahmedabad (India)
Additional Details
Clinical BA/BE